解读《加拿大二膦酸盐相关性下颌骨坏死诊疗指南共识》

Explanation of "Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw"

随着二膦酸盐广泛地应用于治疗骨质疏松症、恶性肿瘤相关的骨骼疾病等，二膦酸盐引起的下颌骨坏死（ONJ）逐渐引起人们的关注，它是一种罕见而严重的并发症。为此，加拿大口腔及颌面外科学会组织了国内外的多学科专家，通过对ONJ相关的文献进行了系统的复习，制定了二膦酸盐相关性ONJ诊疗指南。目的为临床医生提供一个诊断、预防及治疗二膦酸盐相关性ONJ的建议。笔者翻译了指南共识的相关内容，供临床医生参考。

Osteoporosis is becoming more common nowadays. Bisphosphonates have become a cornerstone in the management of osteoporosis, skeletal complications of malignancy and other metabolic bone disease. Though these agents offer great benefit to those with malignancy or metabolic bone disease, there are some side effects reported regarding bisphosphonate-associated osteonecrosis of the jaw （ONJ）. The Canadian Association of Oral and Maxillofacial Surgeons （CAOMS） in association with national and international societies reviewed the current reference of ONJ associated with bisphosphonate and developed recommendations regarding diagnosis, identification of at-risk patients, prevention and management strategies of ONJ caused by bisphosphonates. We here provided partial translation in Chinese from the original paper.